March 17, 2022
Dr. Nigel Key Published: Gene Therapy for Hemophilia
Dr. Nigel Key co-authored a manuscript describing the pivotal multi-center Phase 3 clinical trial of adeno-associated virus 5 (AAV5)- based gene therapy for severe hemophilia A that was published in the New England Journal of Medicine on March 17, 2022. The trial sponsor was Biomarin Pharmaceutical. Of 134 participants with severe hemophilia who were enrolled, …